Garcinia derivative, its preparing method and medicinal use

ABSTRACT

The present invention relates to a field of pharmaceutical chemistry, more specifically, the present invention relates to a garcinia derivative Formula (I), its preparing method, and medicinal use. Wherein the definitions of R 1  and R 2  are disclosed in the specification of the present invention, and the derivative of the present invention is a structurally simplified analogue of the gambogic acid compound; wherein the gambogic acid compound possesses anti-cancer characteristics, and could be used for preparation of anti-tumor drugs.

CROSS-REFERENCE TO RELATED APPLICATION(S)

This application is a National Phase Patent Application and claims thepriority to and benefit of International Application NumberPCT/CN2010/078555, filed on Nov. 9, 2010, which claims priority ofChinese Patent Application Number 201010139385.1, filed on Apr. 2, 2010.

FIELD OF THE INVENTION

The present invention relates to a field of pharmaceutical chemistry,more specifically, the present invention relates to a garciniaderivative, its preparing method, and medicinal use. The derivative ofthe present invention is a structurally simplified analogue of thegambogic acid compound which possesses anti-cancer characteristics andcould be used for the preparation of anti-tumor drugs.

BACKGROUND OF THE INVENTION

It has been recently discovered that the natural product gambogic acidthat is extracted from the gambogic resin of the Garcinia plant, is aneffective ingredient in terms of anti-tumor characteristics. Researchhas shown that gambogic acid could selectively kill the various tumorcells without influencing the human hematopoietic or immune system. Thegambogic acid could also combine with various proteins which are relatedto tumor formation and invasion, and thus induce apoptosis of the tumorcells. Therefore the gambogic acid could be used as an effectiveapoptosis inducer for various tumor systems. The formula of gambogicacid is shown below:

Due to the fact that the molecular weight of gambogic acid is relativelyhigh, the presence of a corresponding group in modified structure mightlead to undesired druggability, furthermore, the gambogic acid isobtained from natural products via extraction and separation, which doesnot facilitate industrial production. A structurally simplified analogueof the gambogic acid has been reported (Compound (II)), however, theanti-pharmaceutical test of the structurally simplified analogue of thegambogic acid (Compound (II)) showed that its anti-tumor activity issignificantly reduced compared to the gambogic acid, thereby leading topoor medicinal properties. (Bioorganic & Medicinal Chemistry 16 (2008)pgs. 4233-4241).

SUMMARY OF THE INVENTION

In the present invention, the structurally simplified analogue which isbased on the gambogic acid caged scaffold structure, is prepared for thefirst time by using a tactic of precursor compound structuralsimplification. The compound of the present invention possesses similaranti-tumor activity when compared with that of gambogic acid, and itcould be used for the preparation of anti-tumor drugs.

The compound structure of the present invention is shown in Formula (I):

Wherein R₁ is a single substituted group or a multi substituted group;when it is the single substituted group, R₁ is a hydroxyl group; andwhen it is the multi substituted group, one of the substituted groups isa hydroxyl group, the rest of substituted groups are selected from anamino group, a hydroxyl group, a nitro group, cyano group, an alkylgroup containing C₁-C₆ carbons, or an alkenyl group containing C₂-C₆carbons. More specifically, R₁ is at least one hydroxyl group, which canbe only substituted by a hydroxyl group, or can be substituted by ahydroxyl group while the other substituted group is selected from one orseveral said substituted groups. Experiments show that the seriescompound of Formula (I), wherein R₁ is at least one hydroxyl group, hashigher compound activity compared to Compound (II).

R₂ is hydrogen, halogen, a hydroxyl group, an alkoxy group containingC₁-C₄ carbons, an amide group containing C₁-C₄ carbons, a carboxylgroup, or an aldehyde group.

The preferred R₁ is a single substituted group, and the preferredsubstituent is a hydroxyl group.

The preferred R₁ is a double substituted group, wherein one preferredsubstituent is a hydroxyl group and another preferred substituent is anisopentene group.

The preferred R₂ is hydrogen, a hydroxyl group, an aldehyde group, acarboxyl group, or an amide group.

The compound of the present invention is prepared via the followingmethods, wherein the reaction formula is:

Wherein the included reagents and conditions are as follows: a. K₂CO₃,KI, chloro-methyl-butyne, CuI and acetone; b. 10% Pd/BaSO₄, ethylacetate; and c. DMF (N,N-dimethyl formamide).

Take the compound wherein R₁ is a hydroxyl group and R₂ is a hydrogen asan example, the said compound could be used as reference for the othersubstituent, the more detailed and preferred preparing method is shownas below:

The compound 3 is obtained from compound 1 and compound 2 via a two-stepreaction. The compound 1 and compound 2 react for 12-18 hours at roomtemperature. The preferred solvent is ethylether and AlCl₃ is added tothe reaction solution. After the reaction, the obtained product withoutany treatment is directly heated to reflux and is then reacted for 20-30hours in the strong alkali. As a result, the compound 3 is obtained. Thepreferred solvents are water and methanol; the ratio between said waterand methanol is 1:1 to 4:1; and inorganic alkali, for instance, NaOH,KOH, and the like is then added to the reaction solution.

The compound 3 is heated and refluxed for 6 hours in a mixed solutioncontaining 40% HBr and glacial acetic acid, as a result, the compound 4is obtained. The solvent ratio between glacial acetic acid: 40% HBr is1:1 to 4:1.

When R₁ is hydroxyl group, the compound 6 is obtained via reactionbetween the compound 5 and diphenyl dichloromethane, wherein thepreferred solvent is xylene or diphenylether and the preferred reactiontemperature is 160° C.-180° C.

The compound 6 reacts with chloromethyl methyl ether at roomtemperature, and as a result, the compound 7 is obtained. The solvent isselected from acetonitrile, N,N-dimethyl formamide (DMF), acetone,dichloromethane, and the like; the reaction time is 6-10 hours; and theinorganic alkali or organic alkali, for instance, NaOH, KOH, K₂CO₃,triethylamine, and the like could be added during the reaction.

The compound 8 is obtained via hydrogenation of the compound 7 at normalpressure, wherein the reaction temperature is 20° C.-50° C.; the solventis selected from THF, acetonitrile, DMF, methanol, trichloromethane, andthe like; and a hydrogenation catalyst should also be added, forinstance, 5% Pd/C, 10% Pd/C, and the like.

When R₁ is the other substituent or chloromethyl methyl, except saidhydroxyl group, the compound 9 is obtained via reaction between thecompound 4 and chloro-methy I-butyne, wherein the reaction temperatureis 60° C.-90° C., and the solvent is selected from DMF, acetone,acetonitrile, dichloromethane, trichloromethane, and the like. Theinorganic alkali or organic alkali, for instance, NaOH, KOH, K₂CO₃,triethylamine, and the like should also be added to the reaction,furthermore, the catalyst CuCl, CuI, or KI should also be added.

The compound 10 is formed via hydrogenation of the compound 9 at normalpressure, wherein the reaction temperature is 20° C.-50° C.; the solventis selected from ethyl acetate, THF, acetonitrile, ethanol, and thelike; a hydrogenation catalyst, for instance, 5% Pd/C, 10% Pd/C, 5%Pd—BaSO₄, 10% Pd—BaSO₄, and the like, should also be added.

The compound 10 is heated to be rearranged, and as a result, thecompound 11 is obtained, wherein the reaction temperature is 120°C.-180° C., and the solvent is selected from toluene, DMF, diphenylether, and the like.

The compound 12 is obtained via oxidation of the compound 11, whereinthe reaction temperature is 25° C.-40° C., and the preferred oxidantsare SnO₂ and t-butyl hydroperoxide, lead tetraacetate, and the like. Thesolvent is selected from toluene, dichloromethane, trichloromethane,DMF, and the like.

When R₁ is double substituted by a hydroxyl group and an isopentenegroup, the compound 5 reacts with chloro-methyl-butyne, and as a result,the compound 13 is obtained, wherein the reaction temperature is 60°C.-90° C., and the solvent is selected from DMF, acetone, acetonitrile,dichloromethane, trichloromethane, and the like. An inorganic alkali ororganic alkali, for instance, NaOH, KOH, K₂CO₃, or triethylamine shouldbe added to the reaction, and CuCl, CuI, or KI should also be added ascatalyst.

The compound 14 is obtained via hydrogenation of the compound 13 atnormal pressure, wherein the reaction temperature is 20° C.-50° C.; thesolvent is selected from ethyl acetate, THF, acetonitrile, ethanol, andthe like; and a hydrogenation catalyst, for instance, 5% Pd/C, 10% Pd/C,5% Pd—BaSO₄, 10% Pd—BaSO₄, and the like should also be added.

The compound 14 is heated to be rearranged, as a result, the compound 15is obtained, wherein the reaction temperature is 120° C.-180° C., andthe solvent is selected from toluene, DMF, diphenyl ether, and the like.

The compound of Formula (I) is purified by a common separation method,for instance, recrystallization, column chromatography, and the like.

The present invention also includes a hydrate, a stereomer, and/or asolvate of compound of Formula (I).

A pharmaceutically acceptable carrier, for instance, a tablet, acapsule, a powder, a syrup, a liquid, a suspension, or an injectioncould be a carrier for the compound of the present invention so as toform normal pharmaceutical preparations, and furthermore, the normalpharmaceutic adjuvants, for instance, a flavor, a sweetening agent, aliquid or solid filler, or a thinner, could also be included in thecarrier for the compound of the present invention.

The compound of the present invention could be served as an oral orinjection manner in the clinical administration.

The clinical dosage of the compound of present invention is 0.01 mg/dayto 1000 mg/day, furthermore, according to the health conditions anddosage types, the clinical dosage which may deviate from said rangecould also be accepted.

The results obtained from the pharmaceutical test show that the compoundof the present invention has relatively strong anti-proliferativeactivity with the tumor cells, which is comparable with that of naturalgambogic acid. Therefore, the compound of the present invention might bean attractive ingredient for use in the development of anti-tumor drugs.

The results obtained from the pharmaceutical test by using partialcompounds of the present invention are as shown below:

Test method: The cells of log phase are cultivated in the culture platewith 96 pores, and each pore contains 100 μL of solution (including1000-1200 tumor cells). The next day, different concentrations of thepresent compound are added to the treatment groups, each compoundcontains 4 to 5 dosage groups, and each dosage group contains at least 3parallel pores. The solvent with an equivalent volume of the saidcompound is added to the control groups. The said culture plate is thenplaced in a 5% CO₂ incubator, cultured at 37° C., and the culturesolution is discharged 4 days later. Next, 200 μL of the 0.2% MTTsolution (RPMI1640 preparation) is added to each pore and incubated at37° C. for 4 hours; the obtained supernatant is discharged; and 150 μLof DMSO is added to each pore so as to dissolve formazane particles.After slightly shaking the mixture, the optical density (OD) is measuredby the ELIASA in the conditions of a resulting reference wavelength 450nm and a detection wavelength 570 nm. The tumor cells treated withsolvent are used as control groups, and the inhibition rate of the drugsagainst the tumor cells and IC50 are calculated according to thefollowing equation. The obtained results are shown in Table 1 whichdisplays the antiproliferative activity of the tumor cells IC₅₀ of thecompound. The MCF-7 cells are human breast cancer cells and the BGC-823cells are human gastric carcinoma cells.

${{Inhibition}\mspace{14mu}{rate}} = {\frac{\begin{matrix}{{{Average}\mspace{14mu}{OD}\mspace{14mu}{of}\mspace{14mu}{comparison}\mspace{14mu}{group}} -} \\{{Average}\mspace{14mu}{OD}\mspace{14mu}{of}\mspace{14mu}{treatment}\mspace{14mu}{group}}\end{matrix}}{{Average}\mspace{14mu}{OD}\mspace{14mu}{of}\mspace{14mu}{comparison}\mspace{14mu}{group}} \times 100\%}$

TABLE 1 Antiproliferative activity of the tumor cells IC₅₀ of thecompound. Corresponding MCF-7 cell BGC-823 cell Compound No. ExamplesIC₅₀ (μM) IC₅₀ (μM) CPUY I-1 Example 1 9.16 3.59 CPUY I-2 Example 412.40 17.60 CPUY I-5 Example 10 5.79 15.00 CPUY I-6 Example 11 11.9021.70 CPUY I-7 Example 12 10.90 18.20 CPUY I-8 Example 13 9.06 11.30 II13.90 20.30 Gambogic acid 2.19 2.35

The present invention possesses the following advantages: the naturalproduct of gambogic acid is not necessary to be used as raw material,instead the structurally simplified analogue of the gambogic acid(Formula (1)) can be directly prepared; the obtained structure is simplein comparison with that of the gambogic acid; the anti-tumor activity isthe same as that of gambogic acid; and the obtained anti-tumor activitythat resulted from the hydroxyl substitution is higher than that of thereported Compound (II).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Example 1

The following formula represents a3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-8-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound (CPUY I-1).

(1) Preparation of 1,5,6-trimethoxy-9H-xanthenone

In preparation of 1,5,6-trimethoxy-9H-xanthenone, 9.6 g (52.8 mmol) of2,6-dimethoxy benzoic acid is dissolved in 140 mL of dried benzene, 24mL of oxalyl chloride is added and mixed at room temperature for 24hours. Subsequently, the solvent and remaining oxalyl chloride areremoved via vacuum distillation; 160 mL of dried ethyl ether is added todissolve the remains; 8.8 g (52.4 mmol) of 1,2,3-trimethoxybenzene isadded; the mixture is stirred for 30 minutes in an ice-bath; 20 g (152mmol) of anhydrate AlCl₃ is added and reacted at room temperature for 20hours; the over amount of AlCl₃ is quenched with the diluted HClsolution (15%) and then extracted with ethyl acetate (2×100 mL); theorganic phase is dried with anhydrous sodium sulfate and condensed; andas a result, 16 g of yellow solid is obtained. The obtained solid isdirectly dispersed in 240 mL of mixed solution containing methanol andwater (methanol: water=5:3) without purification; 23.2 g (58.36 mmol) ofNaOH is added; the mixture is stirred and refluxed at 110° C. for 36hours; 6 mol/L of HCl is added until the pH value is adjusted to 6-8;and as a result, a large amount of solid is precipitated. The saidprecipitation is filtered, and the resulting filter cake is purifiedwith the aid of column chromatography, wherein the eluent is the mixedsolution containing petroleum ether and ethyl acetate (petroleumether:ethyl acetate=4:1), and as a result, 12.8 g white solid isobtained, and the productivity is 85%; m.p. is 144.6° C.-145.7° C.;1H-NMR (300 MHz, CD3COCD3): 3.95 (m, 6H), 4.01 (s, 3H), 6.97 (d, 1H,J1=8.4 Hz, J2=0.6 Hz), 7.14 (d, 1H, J1=8.4 Hz, J2=0.6 Hz), 7.15 (d, 1H,J=9.0 Hz), 7.69 (t, 1H, J=8.4 Hz), 7.89 (d, 1H, J=9 Hz); EI-MS (m/z):286 (M+).

(2) Preparation of 1,5,6-trihydroxy-9H-xanthenone

In preparation of 1,5,6-trihydroxy-9H-xanthenone, 15 g (52.5 mmol) of1,5,6-trimethoxy-9H-xanthenone is dissolved in 500 mL of mixed solution(HBr:acetic acid=1:2), the said mixture is heated to 120° C., andrefluxed for 12 hours. Next, 10% NaOH solution is added until the pHvalue is adjusted to 3-4, and as a result, a large amount of gray solidis precipitated. The said precipitation is filtered, and as a result, 9g of grey solid is obtained, and the productivity is 70%; m.p. is 300°C.-301° C.; ¹H-NMR (300 MHz, DMSO-d6): 6.77 (dd, 1H, J1=8.3 Hz, J2=0.87Hz,), 6.97 (d, 1H, J=8.8 Hz), 67.05 (dd, 1H, J1=8.3 Hz, J2=0.87 Hz),7.57 (d, 1H, J=8.8 Hz), 7.68 (t, 1H, J=8.3 Hz), 9.53 (s, 1H), 10.68 (s,1H), 12.91 (s, 1H); ESI-MS (m/z): 243 ([M−H]−).

(3) Preparation of7-hydroxy-2,2-diphenyl-6H-[1,3]dioxolo[4,5-c]-6-xanthenone

In preparation of7-hydroxy-2,2-diphenyl-6H-[1,3]dioxolo[4,5-c]-6-xanthenone, 5 g (22.3mmol) of 1,5,6-trihydroxy-9H-xanthenone is added to 40 mL of diphenylether, subsequently, 7 mL (35 mmol) of diphenyl dichloromethane isadded, and the mixture reacts at 175° C. for 4 hours. After the reactionsolution is cooled, 800 mL petroleum ether is added, and as a result, alarge amount of gray solid is precipitated. The said precipitation isfiltered and purified with the aid of column chromatography, wherein theeluent is the mixed solution containing petroleum ether and ethylacetate (petroleum ether:ethyl acetate=8:1), and as a result, 6.1 g oflight yellow solid is obtained, and the yield is 79%; m.p. is 203°C.-205° C.; 1H-NMR (300 MHz, CDCl3): 6.72 (d, J=8.4 Hz, 1H), 6.90 (d,J=9.3 Hz, 1H), 6.93 (d, J=9.3 Hz, 1H), 7.34 (m, 6H), 7.49 (t, J=9.3 Hz,1H), 7.57 (m, 4H), 7.82 (d, J=8.4 Hz, 1H), 12.70 (s, 1H); EI-MS (m/z):408.

(4) Preparation of 7-methoxymethylenedioxy-2,2-diphenyl-6H-[1,3]dioxolo[4,5-c]xanthenone

In preparation of 7-methoxymethylenedioxy-2,2-diphenyl-6H-[1,3]-dioxolo[4,5-c]xanthenone, 6.1 g(14.85 mmol) of7-hydroxy-2,2-diphenyl-6-[1,3]dioxolo[4,5-c]-6-xanthenone is dissolvedin 200 mL of acetone, 1.2 g (29.7 mmol) of NaH is added, the mixture ismixed at 0° C. for 0.5 hours, 2.43 mL (29.7 mmol) chloromethyl methylether is added, and at the end of addition, the mixture reacts at roomtemperature for 8 hours. The reaction solution is then poured into 800mL of ice water, and as a result, a large amount of white solid isprecipitated. The said precipitation is filtered and dried, and as aresult, 6 g of white solid is obtained, and the yield is 90%; m.p. is138° C.-140° C.; 1H-NMR (300 MHz, CDCl3): 3.56 (s, 3H), 5.36 (s, 2H),6.94 (d, J=8.4 Hz, 1H), 7.04 (dd, 1H, J1=8.2 Hz, J2=0.6 Hz, 1H), 7.17(dd, J=8.2 Hz, J2=0.6 Hz, 1H), 7.40 (m, 6H), 7.55 (dd, J=8.2H, J2=0.6Hz), 7.64 (m, 4H), 7.89 (d, J=8.4 Hz, 1H); EI-MS (m/z): 452 (M+).

(5) Preparation of 3,4-dihydroxy-7-methoxy methylenedioxy-9H-xanthenone

In preparation of 3,4-dihydroxy-7-methoxy methylenedioxy-9H-xanthenone,6 g (13.2 mmol) of 7-methoxymethylenedioxy-2,2-diphenyl-6H-[1,3]-dioxolo[4,5-c]xanthenone isdissolved in 420 ml of mixed solution containing methanol: THF=1:1, 700mg of 10% Pd/C is added, and the mixture undergoes hydrogenation atnormal pressure for 24 hours. The reaction solution is filtered, thefiltrate is condensed, the residue is purified with the aid of columnchromatography (petroleum ether/ethyl acetate=1:1), and as a result, 3 gof dark green solid is obtained, and the yield is 78.5%; m.p. is greaterthan 300° C.; 1H NMR (300 MHz, DMSO): 3.46 (s, 3H), 5.31 (s, 2H), 6.90(d, 1H, J=8.25 Hz), 7.02 (dd, 1H, J1=8.8 Hz, J2=2.2 Hz), 7.14 (dd,J1=8.8 Hz, J2=2.2 Hz), 7.84 (dd, 1H, J1=8.8 Hz, J2=2.2 Hz), 8.25 (d, 1H,J=8.25 Hz); EI-MS (m/z) 288 (M+), 288, 256, 244.

(6) Preparation of 1-hydroxy-5,6-dimethyl butynyloxy-9H-xanthenone

In preparation of 1-hydroxy-5,6-dimethyl butynyloxy-9H-xanthenone, 3 g(10.2 mmol) of 3,4-dihydroxy-7-methoxy methylenedioxy-9H-xanthenone isdissolved in 200 mL of acetonitrile, and subsequently, KI (1.73 g, 10.2mmol), 1,8-diazabicyclo-dicyclo(5,4,0)-7-undecene (7.2 mL, 57.12 mmol),and CuI (300 mg, 1.6 mmol) are added, respectively. The said mixture isstirred at room temperature for 10 minutes; is placed in an ice-bath;chloro-methyl-butyne (8.4 ml, 81.6 mmol) is added; and the said mixturethen reacts at room temperature for 48 hours.

It is then vacuum distilled to condense acetonitrile; 800 mL of waterand 200 mL of ethyl ether are added; and 2 mol/L of HCl are added untilthe pH value is adjusted to 3. The mixture is stirred at roomtemperature for 4 hours; the water phase is extracted with 800 mL ofethyl acetate four times; the extracted ethyl acetate is dried withanhydrous sodium sulfate; the organic phase is condensed; the resultingresidue is purified with the aid of column chromatography, wherein theeluent is the mixed solution containing petroleum ether and ethylacetate (petroleum ether:ethyl acetate=8:1); and as a result, 2 g ofbrown crystals are obtained, and the productivity is 49%; m.p. is 138°C.-140° C.; 1H-NMR (300 MHz, CDCl3): 1.79 (s, 6H), 1.83 (s, 6H), 2.28(s, 1H), 2.66 (s, 1H), 6.79 (dd, J1=8.1 Hz, J2=0.6 Hz, 1H), 6.95 (dd,J1=8.1 Hz, J2=0.6 Hz, 1H), 7.56 (t, J=8.1 Hz, 1H), 7.66 (d, J=9 Hz, 1H),7.98 (d, J=9 Hz, 1H), 12.71 (s, 1H); EI-MS (m/z): 376, 310, 244.

(7) Preparation of 1-hydroxy-5,6-dimethyl butenyl-9H-xanthenone

In preparation of 1-hydroxy-5,6-dimethyl butenyl-9H-xanthenone,1-hydroxy-5,6-dimethyoxy butynyloxy-9H-xanthenone (2 g, 5.3 mmol) isdissolved in 18 mL of ethanol, 50 mg of 10% Pd/BaSO₄ is added, and themixture undergoes hydrogenation at normal pressure for 12 hours. Theobtained is filtered, the reaction solution is condensed, and theobtained gray solid is washed with petroleum ether and is used directlyin the following step.

(8) Preparation of the3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-8-hydroxy-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound

In preparation of the3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-8-hydroxy-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound, 1.8 g of 1-hydroxy-5,6-dimethylbutenyl-9H-xanthenone is dissolved in 15 mL of DMF and the said mixturereacts at 125° C. for 6 hours. The solvent is evaporated, the resultingresidue is purified with the aid of column chromatography (petroleumether/ethyl acetate=6:1), and as a result, 1.2 g brown solid isobtained, and the yield is 66%. The obtained solid is furthercrystallized in the mixed solution containing acetone and petroleumether (acetone:petroleum ether=1:20), and the brown crystal is obtained,and the m.p. is 130° C.-132° C.; 1H-NMR (300 MHz, CDCl3): 0.95 (s, 3H),1.18-1.25 (m, 4H), 1.30 (s, 3H), 1.61 (s, 3H), 2.26 (dd, J1=13.5 Hz,J2=4.5 Hz, 1H), 2.37 (d, J=9.6, 1H), 2.54 (d, J=7.8 Hz, 2H), 3.44 (dd,J1=6.9 Hz, J2=4.5 Hz, 1H), 4.34 (m, 1H), 6.43 (dd, J1=8.1 Hz, J2=0.9 Hz,1H), 6.45 (dd, J1=8.1 Hz, J2=0.9 Hz, 1H), 7.32 (t, J=8.1 Hz, 1H), 7.41(d, J=9.6 Hz, 1H), 12.00 (s, 1H).

Example 2

The following formula represents a3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-8-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound (CPUY I-1).

(1) Preparation of 5,6-dihydroxyl-1-acetoxy xanthenone

In preparation of 5,6-dihydroxyl-1-acetoxy xanthenone, 5 g (20.5 mmol)of 1,5,6-trihydroxy-9H-xanthenone is dissolved in 35 mL of DMF;subsequently, 5 g of K₂CO₃, 500 mg of KI, and 7 mL (61 mmol) of benzylchloride are added; the said mixture reacts at 65° C. for 2 hours; thereaction solution is cooled and transferred to 2 mol/L of HCl; and as aresult, a large amount of solid is precipitated. The said precipitationis vacuum filtered and dried, and as a result, 8 g of light yellow solid5,6-dibenzyl-1-hydroxyl-xanthenone is obtained. The said obtained solidis directly dissolved in 80 mL of dichloromethane, subsequently, 5 g ofDMAP and 6 mL of acetic anhydride are added in turn, and the saidmixture reacts at a constant temperature of 25° C. for 2 hours. Theobtained reaction solution is washed twice with saturated NH₄Cl solution(80 mL×2) and twice with water (80 mL×2); the obtained organic phase isdried with anhydrous sodium sulfate; and 8 g of white solid5,6-dibenzyl-1-acetyl xanthenone is obtained via vacuum condensation.The said obtained solid is dissolved in 400 mL of mixed solutioncontaining THF and methanol (THF:methanol=1:1), and hydrogenation takesplace under normal pressure with the aid of 10% Pd/C. The said mixturereacts at a constant temperature of 40° C. for 2 hours; the obtainedsubstance is filtered; the filtrate is condensed; 200 mL of petroleumether is added to wash the resulting residue; 4.5 g of grey solid isobtained via vacuum filtration; and the obtained solid is directly usedin the following step without purification.

(2) Preparation of 5,6-dimethyl butynyl-1-acetoxy xanthenone

In preparation of 5,6-dimethyl butynyl-1-acetoxy xanthenone,5,6-dihydroxy-1-acetoxy xanthenone (5 g, 17.5 mmol) is dissolved in 80mL of acetone, and 5 g of K₂CO₃, 5 g of KI, 1 g of CuI, and 7 mL ofchloro-methyl-butyne are added in turn. The said mixture is heated andrefluxed for 5 hours. At the end of the reaction, 300 mL of water and 80mL of ethyl acetate are added and mixed; and the organic phase isseparated and dried with anhydrous sodium sulfate. The obtained isseparated with the aid of column chromatography (petroleum ether: ethylacetate=8:1) and 3 g of yellow solid is obtained, and the yield is 41%;1H-NMR (300 MHz, CDCl₃): 1.76 (s, 3H), 1.82 (s, 3H), 2.31 (s, 1H), 2.50(s, 3H), 2.65 (s, 1H), 6.97 (d, J=7.5 Hz, 1H), 7.42 (d, J=8.4 Hz, 1H),7.59-7.69 (m, 2H), 7.95 (s, J=9 Hz, 1H).

(3) Preparation of 5,6-dimethyl butenyl-1-acetoxy xanthenone

In preparation of 5,6-dimethyl butenyl-1-acetoxy xanthenone,5,6-bis(dimethyl butynyl-1-acetoxy xanthenone (3 g, 12.3 mmol) isdissolved in 70 mL of mixed solution containing ethyl acetate andethanol (ethyl acetate:ethanol=1:3), and undergoes hydrogenation atnormal pressure with the aid of 300 mg 10% Pd—BaSO₄. The obtained reactsat room temperature for 16 hours; the reaction solution is filtered; andthe solvent is condensed and dried in reduced pressure, and is useddirectly in the following step.

(4)3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-8-acetoxy-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound

In preparation of the above compound, 1-hydroxyl-5,6-dimethylbutenyl-9H-xanthenone (1.8 g, 7.3 mmol) is dissolved in 15 mL of DMF andthe said mixture reacts at 125° C. for 6 hours and the solvent isevaporated. The resulting residue is separated with the aid of columnchromatography (petroleum ether: ethyl acetate=6:1), and as a result, 1g of yellow solid is obtained, and the yield is 55.6%; 1H-NMR (300 MHz,CDCl3): 0.99 (s, 3H), 1.18-1.25 (m, 4H), 1.30 (s, 3H), 1.61 (s, 3H),2.26 (dd, J1=13.5 Hz, J2=4.5 Hz, 1H), 2.28 (s, 3H), 2.37 (d, J=9.6, 1H),2.54 (d, J=7.8 Hz, 2H), 3.44 (dd, J1=6.9 Hz, J2=4.5 Hz, 1H), 4.34 (m,1H), 6.43 (dd, J1=8.1 Hz, J2=0.9 Hz, 1H), 6.45 (dd, J1=8.1 Hz, J2=0.9Hz, 1H), 7.32 (t, J=8.1 Hz, 1H), 7.41 (d, J=9.6 Hz, 1H).

(5)3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-8-hydroxyl-1,5-dimethylene1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound

In preparation of the above compound,3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-8-acetoxy-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketone endocyclic compound (1 g, 4mmol) is dissolved in 10 mL of mixed solution containing THF andmethanol (THF:methanol=1:1), subsequently, 4 mL (4 mol/L) of HCl isadded and the mixture is mixed at room temperature for 6 hours, 10 mLethyl acetate and 10 mL 10% NaHCO₃ are added, and the obtained organicphase is separated and dried with anhydrous sodium sulfate. The obtainedis separated with the aid of column chromatography (petroleum ether:ethyl acetate=4:1), and as a result, 810 mg of yellow solid is obtained,and the productivity is 90%; m.p. is 130° C.-132° C.; 1H-NMR (300 MHz,CDCl3): 0.95 (s, 3H), 1.18-1.25 (m, 4H), 1.30 (s, 3H), 1.61 (s, 3H),2.26 (dd, J1=13.5 Hz, J2=4.5 Hz, 1H), 2.37 (d, J=9.6, 1H), 2.54 (d,J=7.8 Hz, 2H), 3.42 (dd, J1=6.9 Hz, J2=4.5 Hz, 1H), 4.33 (m, 1H), 6.43(dd, J1=8.1 Hz, J2=0.9 Hz, 1H), 6.45 (dd, J1=8.1 Hz, J2=0.9 Hz, 1H),7.32 (t, J=8.1 Hz, 1H), 7.41 (d, J=9.6 Hz, 1H), 12.00 (s, 1H).

Example 3

The following formula represents a(E)-3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-hydroxymethyl-2-butenyl)-8-hydroxy-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketone endocyclic compound:

(1) The synthetic method in preparation of3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-8-hydroxy-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound is same as those described in Example 1 and Example2.(2) In preparation of(E)-3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-hydroxymethyl-2-butenyl)-8-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound,

800 mg of3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-8-hydroxy-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound is dissolved in 5 mL of dichloromethane, 80 mg ofSnO₂ and 1 ml of t-butyl hydroperoxide are added, and the said mixtureis stirred at room temperature for 24 hours. After the reaction, theobtained is washed with water three times, the organic phase isseparated, and is then separated again with the aid of columnchromatography (petroleum ether: ethyl acetate=2:1), and as a result,780 mg of yellow solid is obtained, and the yield is 94%.

Example 4

The following formula represents a3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-10-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound (CPUY I-2).

(1) Preparation of 3-hydroxyl-4,6-dimethoxy-9H-xanthenone

In preparation of 3-hydroxyl-4,6-dimethoxy-9H-xanthenone, 2.4 g (13.14mmol) of 2,4-dimethoxy benzoic acid is dissolved in 60 mL of drieddichloromethane, 5 mL of oxalyl chloride is added, and the said mixtureis stirred at room temperature for 24 hours. Once the solvent isevaporated, 80 mL of ethyl ether is added to dissolve resulting residue;2.19 g (13.03 mmol) of 1,2,3-trimethoxy benzene is added; the saidmixture is cooled in an ice-bath for 30 min, 5.0 g of anhydrate AlCl₃(37.5 mmol) is added; the said mixture reacts at room temperature for 12hours; and the over amount of AlCl₃ is quenched with the aid of dilutedHCl solution (15%). The obtained is then extracted with ethyl acetate(80 mL×2) and dried with anhydrous sodium sulfate. The resulting residueis condensed in reduced pressure and is directly dissolved in the mixedsolution containing methanol (20 mL) and 30% NaOH (40 mL). The saidmixture is heated and refluxed for 14 hours, the pH value of theobtained solution is adjusted with the aid of 6 mol/L HCl until the pHvalue reaches 6, the said mixture is vacuum filtered and dried, and as aresult, 3 g of crude product is obtained, and the yield is 81%; m.p. is120.2° C.-121.2° C.; 1H-NMR (300 MHz, CD3COCD3): 3.98-4.03 (m, 9H), 7.00(dd, 1H, J1=8.9 Hz, J2=2.4 Hz), 7.09 (d, 1H, J=2.4 Hz), 7.19 (d, 1H,J=9.0 Hz), 7.95 (d, 1H, J=9.0 Hz), 8.13 (d, 1H, J=8.9 Hz); EI-MS (m/z):286 [M+], 271, 256, 241.

(2) Preparation of 3,4,6-trihydroxyl-9H-xanthenone

In preparation of 3,4,6-trihydroxyl-9H-xanthenone, 8 g (2.79 mmol) of3-hydroxyl-4,6-dimethoxy-9H-xanthenone is dissolved in 160 mL of mixedsolution containing HBr and acetic acid (HBr:acetic acid=1:2) (V: V),the said mixture is heated to 120° C. and refluxed for 12 hours, the pHvalue of the obtained mixture is adjusted with the aid of 10% NaOHsolution until the pH value reaches 3-4, and as a result, a large amountof grey solid is precipitated. It is then vacuum filtered and purifiedwith the aid of silica gel column chromatography (petroleum ether/ethylacetate=1:1), and as a result, 5.8 g of grey solid is obtained, and theyield is 85%; m.p. is greater than 300° C. (reported m.p. is 340°C.-341° C.); 1H-NMR (300 MHz, DMSO-d6): 6.83-6.93 (m, 3H,), 7.50 (d, 1H,J=8.8 Hz), 8.00 (d, 1H, J=8.8 Hz), 9.28 (s, 1H), 10.31 (s, 1H), 10.77(s, 1H), ESI-MS (m/z): 243 ([M−H]−).

(3) Preparation of9-hydroxyl-2,2-diphenyl-6H-[1,3]dioxolo[4,5-c]xanthenone

In preparation of9-hydroxyl-2,2-diphenyl-6H-[1,3]dioxolo[4,5-c]xanthenone, 5 g (21 mmol)of 3,4,6-trihydroxyl-9H-xanthenone is added to 30 mL of diphenyl ether,7 mL (36 mmol) of diphenyl dichloromethane is added, and then the saidmixture reacts at 175° C. for 2 hours. The obtained is cooled, 100 mL ofpetroleum ether is added, and as a result, a large amount of yellowsolid is precipitated. The obtained solid is vacuum filtered andpurified with the aid of filter cake column chromatography, the eluent(petroleum ether/ethyl acetate=4:1) is used, and as a result, 5.1 g ofyellow solid is obtained, and the yield is 61%; m.p. is 231° C.-232° C.;1H-NMR (300 MHz, CD3COCD3): 6.94-6.98 (m, 2H), 7.1 (d, 2H, J=8.7 Hz),7.47˜7.50 (m, 6H), 7.66-7.69 (m, 4H), 7.85 (d, J=8.7 Hz, 1H), 8.10 (q,J=9 Hz, 1H); EI-MS (m/z) 408 [M+], 331, 303, 165.

(4) Synthesis of 9-methoxymethyleneoxy-2,2-diphenyl-6H-[1,3]dioxolo[4,5-c]xanthenone

In preparation of 9-methoxymethyleneoxy-2,2-diphenyl-6H-[1,3]dioxolo[4,5-c]xanthenone, 5 g (2.45mmol) of 9-hydroxyl-2,2-diphenyl-6H-[1,3]dioxolo[4,5-c]xanthenone isdissolved in 70 mL of DM, 515 mg (4.29 mmol) of sodium hydride is added,and the said mixture is mixed for 10 min. Subsequently, 1.8 mL (23 mmol)of chloromethyl methyl ether is added; the said mixture reacts at roomtemperature for 8 hours; 200 mL water is added to the said reactionsolution; the said solution is extracted with 200 mL of ethyl acetatefour times; and the organic phase is condensed. The resulting residue isseparated and purified with the aid of column chromatography (petroleumether/ethyl acetate=4:1), and as a result, 5 g of white solid isobtained, and the yield is 99%; m.p. is 179° C.-181° C.; 1H NMR (300MHz, CDCl3): 3.44 (s, 3H), 5.21 (s, 2H), 6.91-6.96 (m, 2H), 7.10 (s,J1=2.4 Hz, 1H), 7.32-7.36 (m, 6H), 7.54-7.59 (m, 4H), 7.82 (d, 1H, J=5.1Hz), 8.17 (d, 1H, J=5.3 Hz); EI-MS (m/z) 452 (M+), 375, 331, 165, 105.

(5) Preparation of 3,4-dihydroxyl-6-methoxy methyleneoxy-9H-xanthenone

In preparation of 3,4-dihydroxyl-6-methoxy methyleneoxy-9H-xanthenone, 5g (2.2 mmol) of 9-methoxymethyleneoxy-2,2-diphenyl-6H-[1,3]dioxolo[4,5-c]xanthenone is added to90 ml of mixed solution containing ethanol and THF (ethanol: THF=1:1),500 mg of 10% Pd/C is added, and the said mixture undergoeshydrogenation at normal pressure for 24 hours. The obtained reactionsolution is vacuum filtered and the filtrate is condensed. The resultingresidue is separated and purified with the aid of column chromatography(petroleum ether: ethyl acetate=2:1), and as a result, 5 g of lightyellow solid is obtained, and the yield is 90%; m.p. is greater than300° C.; 1H NMR (300 MHz, DMSO-d6): 3.52 (s, 3H), 5.30 (s, 2H), 6.97 (d,J=8.8 Hz, 1H), 7.04-7.07 (q, J1=2.2 Hz, J2=8.8 Hz, 1H), 7.14 (d, J=2.2Hz, 1H), 7.84 (d, J=8.8 Hz, 1H), 8.25 (d, J=8.8 Hz, 1H); EI-MS (m/z) 288(M+), 258, 215, 187, 167.

(6) Preparation of 3,4-dimethyl butynyl-6-methoxymethyleneoxy-9H-xanthenone

In preparation of 3,4-dimethyl butynyl-6-methoxymethyleneoxy-9H-xanthenone, 5 g (16.5 mmol) of xanthenone is dissolvedin 80 mL of acetonitrile, and subsequently, 2.5 g (20 mmol) of KI, 9.5mL of DBU, and 250 mg (0.028 mmol) of CuI are added in turn. Then 0.42ml (3.3 mmol) of chloro-methyl butyne is added; the said mixture reactsat room temperature for 24 hours; 800 mL water is added; the saidmixture is stirred at room temperature for 15 min; the obtained waterphase is extracted with 200 mL ethyl acetate four times; and theobtained organic phase is condensed. The resulting residue is separatedand purified with the aid of column chromatography, the eluent(petroleum ether/ethyl acetate=8:1) is used, and as a result, 3.5 g oforange powder is obtained, and the yield is 45%; m.p. is 128° C.-130°C.; 1H-NMR (300 MHz, CDCl₃): 1.69 (s, 6H), 1.75 (s, 6H), 2.26 (s, 1H),2.58 (s, 1H), 3.45 (s, 3H), 5.22 (s, 1H), 6.96 (d, J1=8.7 Hz, J2=2.1 Hz,1H), 7.04 (d, J=2.1 Hz, 1H), 7.54 (d, J=9 Hz, 1H), 7.97 (s, J=9 Hz, 1H),8.18 (d, J=8.7 Hz, 1H); EI-MS (m/z): 420, 405, 377, 354, 339, 324, 309,295, 288, 244.

(7) Preparation of 2-methoxy methyleneoxy-5,6-dimethylbutenyl-9H-xanthenone

In preparation of 2-methoxy methyleneoxy-5,6-dimethylbutenyl-9H-xanthenone, 3.5 g of xanthenone is dissolved in 80 mL ofethanol, 350 mg of 10% Pd—BaSO₄ is added, and the said mixture undergoeshydrogenation at room temperature for 2 hours. The obtained reactionsolution is vacuum filtered and the obtained filtrate is condensed. Theresulting residue is separated and purified with the aid of columnchromatography, the eluent (petroleum ether/ethyl acetate=8:1) is used,and as a result, 3 g of colorless oil is obtained, the yield is 89%, andthe said obtained is used directly in the following reaction step.

(8) Preparation of3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-10-methoxymethyleneoxy-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketone

In preparation of3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-10-methoxymethyleneoxy-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketone, 3g of 2-methoxy methyleneoxy-5,6-methyl butenyl-9H-xanthenone isdissolved in 30 mL of DMF, the said mixture reacts at 125° C. for 6hours, and the solvent is evaporated. The obtained residue is separatedand purified with the aid of column chromatography, and as a result, 1.4g of white solid is obtained, and the yield is 45%; m.p. is 168° C.-169°C.; 1H-NMR (300 MHz, CDCl3): 0.92 (s, 3H), 1.17-1.29 (m, 7H), 1.63 (s,3H), 2.24 (dd, J1=13.5 Hz, J2=4.5 Hz, 1H), 2.37 (d, J=9.6, 1H), 2.51 (d,J=9.3 Hz, 2H), 3.36-3.44 (m, 4H), 4.36 (m, 1H), 5.15 (s, 2H), 6.57 (d,J=2.1 Hz, 1H), 6.64 (dd, J1=8.7 Hz, J2=2.1 Hz, 1H), 7.31 (d, J=6.9 Hz,1H), 7.80 (d, J=8.7 Hz, 1H); IR (KBr): 2974.4, 2909.6, 1737.2, 1647.4,1611.2, 1499.2, 1438.5, 1290.5, 1150.5, 1079.2, 1009.2, 982.4; EI-MS(m/z): 424, 396, 381, 368, 353, 327, 299, 285, 257; Anal. Calcd forC25H28O6(%): C, 70.74; H, 6.65. Found: C, 70.64; H, 6.95.

(9) Preparation of3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-10-hydroxy-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketone

In preparation of3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-10-hydroxy-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketone,1.4 g of3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-10-methoxymethyleneoxy-1,5-dimethylene-1H,7H-furan[3,4-d]xanthenoid-7,13-diketoneis dissolved in 18 mL of mixed solution containing dichloromethane andethyl ether (dichloromethane: ethyl ether=1:1), the said mixture iscooled in an ice-bath, 10 mL of concentrated HCl is added, and the saidmixture reacts at room temperature for 1 hour. After the reaction, thesaid reaction solution is extracted with ethyl acetate, and washed withsaturated NaCl solution. The ethyl ester phase is dried and condensed,and then separated and purified with the aid of column chromatography,the eluent (petroleum ether/ethyl acetate=4:1) is used, and as a result,686 mg of yellow solid is obtained, and the yield is 50%; m.p. is 197°C.-199° C.; 1H-NMR (300 MHz, DMSO): 1.02 (s, 3H), 1.22-1.33 (m, 7H),1.68 (s, 3H), 2.31 (dd, J1=13.5 Hz, J2=3.9 Hz, 1H), 2.42-2.57 (m, 3H),3.49 (d, J=6.6 Hz, 1H), 4.4 (m, 1H), 6.46 (s, 1H), 6.63 (d, J=9 Hz, 1H),7.37 (d, J=6.9 Hz, 1H), 7.46 (d, J=9, 1H); IR (KBr): 3376, 3275.5,2970.6, 2927.1, 1738, 1650, 1607, 1584, 1493, 1332, 1278, 1233.5, 1146,958, 866, 745; EI-MS (m/z): 379 ([M−H]+); Anal. Calcd for C₂₃H₂₄O₅(%):C, 72.61%; H, 6.36%. Found: C, 72.29%; H, 6.54%.

Example 5

The following formula represents a3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-hydroxymethyl-2-butenyl)-10-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound:

The3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-10-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketonecompound is used as a starting material, the operating procedures arethe same as those described in Example 3, and as a result, 746 mg ofyellow solid is obtained, and the total yield is 4%.

Example 6

The following formula represents a3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-9-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound (CPUY I-3).

Similar to Example 4, except that the compound 2,5-dimethyoxybenzoicacid is used instead of 2,4-dimethoxy benzoicacid, and as aresult, 690 mg of yellow solid is obtained, and the yield is 3.3%; m.p.is 158° C.-159° C.; 1H-NMR (300 MHz, CDCl₃): 0.91 (s, 3H), 1.18-1.31 (m,7H), 1.65 (s, 3H), 2.27 (dd, J1=13.5 Hz, J2=4.5 Hz, 1H), 2.46 (d, J=9.6,1H), 2.62 (d, J=9.3, 2H), 3.52 (t, J=4.5 Hz, 1H), 4.34 (m, 1H), 6.04 (s,1H), 6.91 (d, J=9 Hz, 1H), 7.06 (dd, J1=9 Hz, J2=3 Hz, 1H), 7.35 (d,J=6.9 Hz, 1H), 7.41 (d, J=3 Hz, 1H), EI-MS (m/z): 380 [M+], 352, 337,283, 255, 213; Anal. Calcd for C₂₃H₂₄O₅(%): C, 72.61%; H, 6.36%. Found:C, 72.33%; H, 6.50%.

Example 7

The following formula represents a3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-hydroxymethoxy-2-butenyl)-9-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound.

The3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-9-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound is used as starting material, the rest of theprocedures are the same as those described in Example 3, and as aresult, 753 mg of yellow solid is obtained, and the total yield is 4%.

Example 8

The following formula represents a3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-11-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound (CPUY I-4).

Similar to Example 4, except that the compound 2,3-dimethoxy benzoicacid is used as a starting material instead of 2,4-dimethoxy benzoicacid, and as a result, 820 mg of yellow solid is obtained, and the yieldis 5%; m.p. is 203° C.-205° C.; 1H NMR (300 MHz, DMSO): 0.82 (s, 3H),1.19-1.34 (m, 7H), 1.64 (s, 3H), 2.27 (dd, J1=13.5 Hz, J2=4.5 Hz, 1H),2.46-2.56 (m, 3H), 3.45 (m, 1H), 4.45 (m, 1H), 5.38 (s, 1H), 6.90 (t,J=8.1 Hz, 1H), 7.11 (dd, J1=7.8 Hz, J1=1.2 Hz, 1H), 7.43 (d, 1H), 7.46(d, J=9 Hz, 1H); IR (KBr): 3425, 2966.2, 2925.1, 1738.22, 1650, 1607,1583, 1493, 1377, 1279, 1233.9, 1152, 748.9; EI-MS (m/z): 380, 352, 337,309, 283, 255, 241, 213; Anal. Calcd for C23H24O5(%): C, 72.61%; H,6.36%. Found: C, 72.60%; H, 6.70%.

Example 9

The following formula represents a3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-hydroxymethoxy-2-butenyl)-11-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound.

The3,3a,4,5-tetrahydro-3,3-dimethyl-1-(3-methyl-2-butenyl)-11-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound is used as a starting material, the rest ofprocedures are same as those described in Example 3, and as a result,755 mg of yellow solid is obtained, and the yield is 4%.

Example 10

The following formula represents a3,3a,4,5-tetrahydro-3,3-dimethyl-1,11-bis(3-methyl-2-butenyl)-10-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound (CPUY I-5).

(Step 1) Preparation of 3,4,6-trimethyl butynyl-9H-xanthenone

In preparation of 3,4,6-trimethyl butynyl-9H-xanthenone, 2.7 g (11.07mmol) of 3,4,6-trimethyl-9H-xanthenone is dissolved in 100 mL ofacetone; subsequently, 7.34 g (44.18 mmol, 4 equiv) of KI, 6.1 g (44.28mmol, 4 equiv) of K₂CO₃ and 0.21 g (0.8 mmol, 0.1 equiv) of CuI areadded in turn; the said mixture is stirred at room temperature for 15min; 7.29 ml (66.42 mmol, 6 equiv) chloro-methyl butyne is added; andthe said mixture reacts at 50° C. for 6 hours. The reaction solution isvacuum filtered and the filtrate is condensed. The resulting residue isseparated and purified with the aid of column chromatography, the eluent(petroleum ether/ethyl acetate=8:1) is used, and as a result, 2.4 g oforange solid is obtained, and the yield is 49%; m.p. is 117° C.-119° C.,¹H NMR (300 MHz, CDCl₃): δ 1.76 (s, 12H), 1.82 (s, 6H), 2.33 (s, 1H),2.65 (s, 1H), 2.69 (s, 1H), 7.16 (dd, J1=8.7 Hz, J1=2.1 Hz, 1H), 7.40(d, J=2.1 Hz, 1H), 7.62 (d, J=9.0 Hz, 1H), 8.04 (d, J=9.0 Hz, 1H), 8.22(d, J=8.7 Hz, 1H), EI-MS (m/z): 442, 427, 376, 361, 324, 310, 281, 244.

(Step 2) Preparation of 3,4,6-trimethyl butenyl-9H-xanthenone

In preparation of 3,4,6-trimethyl butenyl-9H-xanthenone, 200 mg of2,5,6-trimethyl butynyl-9H-xanthenone (22) and (0.45 mmol) of xanthenoneare dissolved in 30 mL of ethanol, 20 mg of 10% Pd/BaSO₄ is added, andthe said mixture reacts at room temperature for 4 hours. The obtainedreaction solution is vacuum filtered and the filtrate is condensed. Theresulting residue is separated and purified with the aid of columnchromatography, the eluent (petroleum ether/ethyl acetate=8:1) is used,and as a result, 170 mg of light green oil is obtained, and the yield is85%; 1H NMR (300 MHz, CDCl₃): 1.56 (s, 12H), 1.60 (s, 6H), 5.16˜5.28 (m,6H), 6.11˜6.34 (m, 3H), 6.95 (dd, J1=9 Hz, J2=2.1 Hz, 1H), 7.05˜7.10 (m,2H), 7.89 (d, J=9 Hz, 1H), 8.14 (d, J=9.0 Hz, 1H), EI-MS (m/z): 448,436, 420, 405, 380, 365, 325, 312, 256, 244.

(3) Preparation of3,3a,4,5-tetrahydro-3,3-dimethyl-1,11-bis(3-methyl-2-butenyl)-10-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketone

In preparation of3,3a,4,5-tetrahydro-3,3-dimethyl-1,11-bis(3-methyl-2-butenyl)-10-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketone,120 mg of 2,5,6-trimethyl butenyl-9H-xanthenone (23) is dissolved in 120ml of DMF, the said mixture reacts at 125° C. for 4 hours, andsubsequently, the DMF is heated and vacuum evaporated. the resultingresidue is separated and purified with the aid of column chromatography,the eluent (petroleum ether/ethyl acetate=4:1) is used, and as a result,65 mg of yellow solid is obtained, and the yield is 53%. The obtained iscrystallized with 95% ethanol, and as a result, the orange fine crystalis obtained, and the m.p. is 158° C.-160° C.; 1H NMR (300 MHz, CDCl₃):0.93 (s, 3H), 1.29-1.33 (m, 7H), 1.71 (s, 3H), 1.77 (s, 3H), 1.83 (s,3H), 2.33 (dd, J1=13.5 Hz, J2=4.5 Hz, 1H), 2.50 (d, J=9.3, 1H), 2.57 (d,J=8.7 Hz, 2H), 3.46-3.55 (m, 3H), 4.40-4.45 (m, 1H), 5.28 (t, J=6.6 Hz,1H), 6.30 (s, 1H), 6.58 (d, J=8.7 Hz, 1H), 7.43 (d, J=6.9 Hz, 1H), 7.80(d, J=8.7 Hz, 1H), IR (KBr): 3438.7, 2964.3, 2922.1, 2849.9, 1738.9,1649.6, 1605.3, 1433.0, 12984.6, 1262.8, 1079.6, 1046.7, 802, EI-MS(m/z): 448, 420, 405, 377, 351, Anal. calcd for C₂₈H₃₂O₅.H₂O (%): C,72.08; H, 7.35. Found: C, 72.33; H, 7.36.

Example 11

The following formula represents a3,3a,4,5-tetrahydro-3,3-dimethyl-1,8-bis(3-methyl-2-butenyl)-9-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketoneendocyclic compound (CPUY I-6).

Similar to the procedures described in Example 10, except that thecompound 2,5,6-hydroxyl-9H-xanthenone is used as a starting materialinstead of 3,4,6-trimethyl-9H-xanthenone, and as a result, 80 mg oforange solid is obtained, and the yield is 40%; m.p. is 138° C.-139° C.;1H NMR (300 MHz, CDCl₃): δ 1.03 (s, 3H), 1.16-1.23 (m, 4H), 1.32 (s,3H), 1.63 (s, 3H), 1.67 (s, 3H), 1.77 (s, 3H), 2.22 (dd, J1=13.5 Hz,J2=4.5 Hz, 1H), 2.29 (d, J=9.6, 1H), 2.56 (d, J=8.7 Hz, 2H), 3.38 (dd,J1=6.9 Hz, J2=4.5 Hz, 1H), 3.88 (d, J=6.6, 2H), 4.38 (t, J=8.7 Hz, 1H),5.13 (t, J=6.6, 1H), 5.39 (s, 1H), 6.81 (d, J=9 Hz, 1H), 7.00 (d, J=9Hz, 1H), 7.18 (d, J=6.9 Hz, 1H), IR (KBr): 3506.1, 3171.6, 2967.4,2918.6, 1737.0, 1659.6, 1606.3, 1486.0, 1443.5, 1376.5, 1298.6, 1221.8,1145.25, 1042.6, 822.7, 790.5, EI-MS (m/z): 448, 420, 378, Anal. calcdfor C₂₈H₃₂O₅.H₂O (%): C, 72.08; H, 7.35. Found: C, 72.10; H, 7.30.

Example 12

The following formula represents a1,3a,4,11a-tetrahydro-3,3-dimethyl-1,7-bis(3-methyl-2-butenyl)-8-hydroxyl-3H-1,4-a-dimethylene-10H-furan[3,4-b]xanthene-10,12-diketoneendocyclic compound (CPUY I-7).

Similar to the procedure described in Example 10, except that thecompound 2,5,6-hydroxyl-9H-xanthenone is used as a starting materialinstead of 3,4,6-trimethyl-9H-xanthenone, and as a result, 40 mg oforange crystals are obtained, and the yield is 20%; m.p. is 148° C.-150°C.; 1H NMR (300 MHz, CDCl₃): 1.30 (s, 3H), 1.33 (s, 3H), 1.52 (s, 3H),1.64 (s, 3H), 1.67 (s, 3H), 1.76 (s, 4H), 2.01 (dd, J1=8.4 Hz, J2=14.7Hz, 1H), 2.10 (dd, J1=4.5, J1=9.9, 1H), 2.56 (d, J=8.7 Hz, 2H), 3.65(dd, J1=6.9 Hz, J2=4.5 Hz, 1H), 3.82 (d, J=6.6, 2H), 4.95 (t, J1=6.9 Hz,J2=8.1 Hz, 1H), 5.11 (m, 2H), 6.96 (s, 2H), 7.00 (d, J=6.9 Hz, 1H), IR(KBr): 3506.1, 3171.6, 2967.4, 2918.6, 1737.0, 1659.6, 1606.3, 1486.0,1443.5, 1376.5, 1298.6, 1221.8, 1145.25, 1042.6, 822.7, 790.5, ESI-MS(m/z): 447 ([M+H]⁺), Anal. calcd for C₂₈H₃₂O₅.H₂O (%): C, 72.08; H,7.35. Found: C, 72.11; H, 7.40.

Example 13

The following formula represents a3,3a,4,5-tetrahydro-3,3-dimethyl-1,10-bis(3-methyl-2-butenyl)-11-hydroxyl-1,5-dimethylene-1H,7H-furan[3,4-d]xanthene-7,13-diketone endocyclic compound (CPUYI-8).

Similar to the procedure described in Example 10, except that thecompound 3,4,5-trihydroxyl-9H-xanthenone is used as starting a materialinstead of 3,4,6-trimethyl-9H-xanthenone, and as a result, 60 mg ofyellow solid is obtained, and the yield is 40%; m.p. is 157° C.-158° C.;1H NMR (300 MHz, CDCl₃): 0.81 (s, 3H), 1.24-1.29 (m, 7H), 1.64 (s, 3H),1.67 (s, 3H), 1.68 (s, 3H), 2.27 (dd, J1=13.5 Hz, J2=4.8 Hz, 1H),2.45-2.49 (m, 3H), 3.33 (d, J=7.2 Hz, 2H), 3.43 (dd, J1=6.6 Hz, J2=4.8Hz, 1H), 4.47 (t, J=6.6 Hz, 1H), 5.20 (dd, J1=7.2 Hz, J2=1.2 Hz, 1H),5.41 (s, 1H), 6.79 (d, J=8.1 Hz, 1H), 7.37 (d, J=8.1 Hz, 1H), 7.41 (d,J=6.6 Hz, 1H), IR (KBr): 3416.4, 2969.4, 2909.6, 1739.5, 1654.8, 1607.8,1448, 1313.7, 1249.2, 1213.7, 1037.7, EI-MS (m/z): 448, 436, 420, 405,377, 351, 323, 281, Anal. calcd for C28H32O5.CH3OH (%): C, 72.08; H,7.35. Found: C, 72.02; H, 7.30.

What is claimed is:
 1. A compound of Formula (I) or its pharmaceuticallyacceptable salt:

wherein R₁ is a single substituent or a multi substituent group; when R₁is the single substituent group, R₁ is a hydroxyl group; and when R₁ isthe multi substituent group, one of the substituent groups is a hydroxylgroup, and the rest of the substituent groups are selected from an aminogroup, a nitro group, a cyano group, an alkyl group containing C₁-C₆carbons, or an alkenyl group containing C₂-C₆ carbons; wherein R₂ ishalogen, a hydroxyl group, an alkoxy group containing C₁-C₄ carbons, anamide group containing C₁-C₄ carbons, a carboxyl group, or an aldehydegroup.
 2. The compound of Formula (I) or its pharmaceutically acceptablesalt according to claim 1, wherein R₁ is a single substituent hydroxylgroup.
 3. The compound of Formula (I) or its pharmaceutically acceptablesalt according to claim 1, wherein R₁ is a double substituent group,wherein one of the substituent groups is a hydroxyl group, and the othersubstituent group is an isopentene group.
 4. The compound of Formula (I)or its pharmaceutically acceptable salt according to claim 1, wherein R₂is a hydroxyl group, an aldehyde group, or a carboxyl group.
 5. A methodfor preparing the compound of claim 1 wherein R₂ is a hydroxyl group,the method comprising: preparing compound 9 from compound 4 underreaction condition a:

preparing compound 10 from compound 9 under reaction condition b:

preparing compound 11 from compound 10 under reaction condition c:

and preparing the compound of Formula (I) from compound 11 underreaction condition d; wherein R₁ is the same as in claim 1; a, b and care reaction conditions: a is K₂CO₃, KI, chloro-methyl-butyne, CuI andacetone; b is 10% Pd/BaSO₄ and ethyl acetate; c is N,N-dimethylformamide; and d is oxidation.
 6. A pharmaceutical composition,comprising the compound of Formula (I) or its pharmaceuticallyacceptable salt according to claim 1 and pharmaceutically acceptablecarrier thereof.
 7. A method of treating breast cancer or gastriccarcinoma, comprising: administering the compound of Formula (I) or itspharmaceutically acceptable salt according to claim 1.